MicroRNAs 与胃癌早期诊断、化疗耐药及预后的作用机制研究进展

胡君璧，赵艳，李雅睿，任牡丹，卢新兰，张丹，卢桂芳，和水祥

（西安交通大学第一附属医院消化内科，陕西 西安，710061）

浏览次数：89次 下载次数：300次

摘要：

胃癌是世界范围内最常见的恶性肿瘤之一。由于胃癌早期缺乏特异性临床症状，患者确诊时常已处于进展阶段。进展 期胃癌往往需要联合化疗，但由于化疗多药耐药的存在，常导致疗效不佳。而确诊晚、化疗耐药等一系列问题严重影响了胃 癌的预后。因此，提高胃癌的早期诊断率，监测预后情况，清晰了解胃癌耐药的相关机制并进行靶向治疗对提高胃癌整体生 存率至关重要。大量研究表明，microRNAs（miRNAs）参与胃癌的侵袭、转移、预后及化疗耐药等。此篇综述总结了近期发现的 与胃癌诊断、预后、耐药等相关的miRNAs，如miRNA-627、miRNA-629、miRNA-652（诊断），miRNA-10b、miRNA-21、miRNA-223、miRNA-338、let-7a、miRNA-30a-5p、miRNA-126（预后），miRNA-181b 和miRNA-497（耐药），有利于胃癌相关生物学标志物研究的发展。

关键词：胃癌；miRNAs；诊断；预后；化疗耐药

中图分类号：R735.2文献标志码：A文章编号：2096-1413(2017)35-0187-04

The research progress of the mechanism of microRNAs in early diagnosis, chemotherapy resistance

and prognosis of gastric cancer
HU Jun-bi, ZHAO Yan, LI Ya-rui, REN Mu-dan, LU Xin-lan, ZHANG Dan, LU Gui-fang, HE Shui-xiang


(Gastroenterolgy Department, the First Affiliated Hospital of Xi``an Jiaotong University, Xi``an 710061, China)

ABSTRACT: Gastric cancer is one of the most common malignant tumors worldwide. Since the gastric cancer is lack of specific symptoms in the early stage, patients are generally diagnosed at a rather advanced stage. Patients with advanced gastric cancer are subject to receiving surgery combining with chemotherapy. However, the acquisition of drug resistance always leads to poor curative effects. All of these seriously influence the prognosis of gastric cancer. Thus, it is significantly important to enhance the early diagnosis, screening and understanding of mechanisms of drug resistance, as well as comducting targeted treatment for enhancing the overall survival. Numerous researches indicates that microRNAs (miRNAs) play a pivotal role in the invasion, metastasis, chemoresistance and prognosis of gastric cancer. This review summarizes some recently identified miRNAs, which are related with the diagnosis, chemotherapy and prognosis of gastric cancer such as miRNA-627, miRNA-629, miRNA-652 (diagnosis), miRNA-10b, miRNA-21, miRNA-223, miRNA-338, let-7a, miRNA-30a-5p and miRNA-126 (prognosis), miRNA-181b, miRNA-497 (chemotherapy). This will be beneficial to the study development of biomarkers for gastric cancer.
KEYWORDS: gastric cancer; miRNA; diagnosis; prognosis; chemoresistance

参考文献：
[1] JEMAL A,BRAY F,CENTER MM,et al.Global cancer statistics[J].CA Cancer J Clin,2011,61(2):69-90.
[2] UEDA T,VOLINIA S,OKUMURA H,et al.Relation between microRNA expression and progression and prognosis of gastric cancer: a microRNA expression analysis[J].Lancet Oncol,2010,11(2):136-146.
[3] CHU D,ZHAO Z,LI Y,et al.Increased microRNA-630 expression in gastric cancer is associated with poor overall survival[J].PLoS One,2014, 9(3):e90526.
[4] LIN Y,UEDA J,KIKUCHI S,et al.Comparative epidemiology of gastric cancer between Japan and China[J].World J Gastroenterol,2011,17 (39):4421-4428.
[5] INOUE M,TSUGANE S.Epidemiology of gastric cancer in Japan [J]. Postgrad Med J,2005,81(957):419-424.
[6] DEHGHANZADEH R,JADIDI -NIARAGH F,GHARIBI T,et al.MicroRNA-induced drug resistance in gastric cancer[J].Biomed Pharmacother,2015(74):191-199.
[7] KROL J,KRZYZOSIAK WJ.Structure analysis of microRNA precursors[J].Methods Mol Biol,2006(342):19-32.
[8] SHAH AA,MEESE E,BLIN N.Profiling of regulatory microRNA transcriptomes in various biological processes: a review [J].J Appl Genet, 2010,51(4):501-507.
[9] IORIO MV,CROCE CM.MicroRNA dysregulation in cancer: diagnostics, monitoring and therapeutics. A comprehensive review[J].EMBO Mol Med,2012,4(3):143-159.
[10] CHEN F,HU SJ.Effect of microRNA-34a in cell cycle, differentiation, and apoptosis: a review[J].J Biochem Mol Toxicol,2012,26(2):79-86.
[11] YANOKURA M,BANNO K,KOBAYASHI Y,et al.MicroRNA and endometrial cancer: roles of small RNAs in human tumors and clinical applications (Review)[J].Oncol Lett,2010,1(6):935-940.
[12] GUO LH,LI H,WANG F,et al.The tumor suppressor roles of miR-433 and miR-127 in gastric cancer[J].Int J Mol Sci,2013,14(7):14171-14184.
[13] CHAN SH,WU CW,LI AF,et al.miR -21 microRNA expression in human gastric carcinomas and its clinical association[J].Anticancer Res, 2008,28(2A):907-911.
[14] CHOI H,CHANG JW,JUNG YK.Peroxiredoxin 6 interferes with TRAIL-induced death-inducing signaling complex formation by binding to death effector domain caspase[J].Cell Death Differ,2011,18(3):405-414.
[15] AJANI JA,BENTREM DJ,BESH S,et al.Gastric cancer, version 2.2013: featured updates to the NCCN guidelines [J].J Natl Compr Canc Netw,2013,11(5):531-546.
[16] LU J,GETZ G,MISKA EA,et al.MicroRNA expression profiles classify human cancers[J].Nature,2005,435(7043):834-838.
[17] LIU X,KWONG A,SIHOE A,et al.Plasma miR-940 may serve as a novel biomarker for gastric cancer[J].Tumour Biol,2016,37 (3):3589 -3597.
[18] SHIN VY,NG EK,CHAN VW,et al.A three -miRNA signature as promising non-invasive diagnostic marker for gastric cancer[J].Mol Cancer,2015(14):202.
[19] ZHANG J,SONG Y,ZHANG C,et al.Circulating MiR -16 -5p and MiR-19b-3p as two novel potential biomarkers to indicate progression of gastric cancer[J].Theranostics,2015,5(7):733-745.
[20] YUE S,SHI H,HAN J,et al.Prognostic value of microRNA-126 and CRK expression in gastric cancer[J].Onco Targets Ther,2016(9):6127-6135.
[21] QIU X,ZHU H,LIU S,et al.Expression and prognostic value of microRNA-26a and microRNA-148a in gastric cancer[J].J Gastroenterol Hepatol,2016,32(4):819-827.
[22] LI X,ZHANG Y,ZHANG Y,et al.Survival prediction of gastric cancer by a seven-microRNA signature[J].Gut,2010,59(5):579-585.
[23] LIU X,GE X,ZHANG Z,et al.MicroRNA-940 promotes tumor cell invasion and metastasis by downregulating ZNF24 in gastric cancer[J]. Oncotarget,2015,6(28):25418-25428.
[24] XIN SY,FENG XS,ZHOU LQ,et al.Reduced expression of circulating microRNA-218 in gastric cancer and correlation with tumor invasion and prognosis[J].World J Gastroenterol,2014,20(22):6906-6911.
[25] RIQUELME I,LETELIER P,RIFFO -CAMPOS AL,et al.Emerging role of mirnas in the drug resistance of gastric cancer[J].Int J Mol Sci, 2016,17(3):424.
[26] BALKO JM,BLACK EP.A gene expression predictor of response to EGFR-targeted therapy stratifies progression-free survival to cetuximabin KRAS wild-type metastatic colorectal cancer[J].BMC Cancer,2009(9): 145.
[27] KIM CH,KIM HK,RETTIG RL,et al.miRNA signature associated with outcome of gastric cancer patients following chemotherapy[J].BMC Med Genomics,2011(4):79.
[28] WANG P,LI Z,LIU H,et al.MicroRNA-126 increases chemosensitivity in drug-resistant gastric cancer cells by targeting EZH2[J].Biochem Biophys Res Commun,2016,479(1):91-96.
[29] MAO L,SUN AJ,WU JZ,et al.Involvement of microRNAs in HER2 signaling and trastuzumab treatment[J].Tumour Biol,2016,[Epub ahead of print].
[30] MERHAUTOVA J,DEMLOVA R,SLABY O,et al.MicroRNA-based therapy in animal models of selected gastrointestinal cancers [J].Front Pharmacol,2016(7):329.
[31] CORREA-GALLEGO C,MADDALO D,DOUSSOT A,et al.Circulating plasma levels of microRNA -21 and microRNA -221 are potential diagnostic markers for primary intrahepatic cholangiocarcinoma [J].PLoS One,2016,11(9):e0163699.
[32] TAKEUCHI -YORIMOTO A,YAMAURA Y,KANKI M,et al.MicroRNA -21 is associated with fibrosis in a rat model of nonalcoholic steatohepatitis and serves as a plasma biomarker for fibrotic liver disease[J].Toxicol Lett,2016(258):159-167.